Prognosis by C-reactive protein and matrix metalloproteinase-9 levels in stable coronary heart disease during 15 years of follow-up

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 22, Issue 8, 2012, Pages 677-683

  Eldrup, N ^a,b   Kragelund, C ^c   Steffensen, R ^d   Nordestgaard, B G ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Rigshospitalet   (Denmark)

^d HILLERØD HOSPITAL   (Denmark)

Author keywords

C reactive protein; Coronary heart disease; Matrix metalloproteinase 9

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; GELATINASE B;

AGED; ARTICLE; BLOOD; CAUSE OF DEATH; CHI SQUARE DISTRIBUTION; CORONARY ARTERY DISEASE; DENMARK; DISEASE COURSE; ENZYMOLOGY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; IMMUNOLOGY; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MORTALITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TIME; UNSTABLE ANGINA PECTORIS; UPREGULATION;

AGED; ANGINA, UNSTABLE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CAUSE OF DEATH; CHI-SQUARE DISTRIBUTION; CORONARY DISEASE; DENMARK; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; UP-REGULATION;

ANGINA;

EID: 84864027345     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2010.11.003     Document Type: Article

References (23)

1. Blankenberg S., Rupprecht H.J., Poirier O., Bickel C., Smieja M., Hafner G., et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003, 107:1579-1585.
2. Eldrup N., Gronholdt M.L., Sillesen H., Nordestgaard B.G. Elevated matrix metalloproteinase-9 associated with stroke or cardiovascular death in patients with carotid stenosis. Circulation 2006, 114:1847-1854.
3. Danesh J., Wheeler J.G., Hirschfield G.M., Eda S., Eiriksdottir G., Rumley A., et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. The New England Journal of Medicine 2004, 350:1387-1397.
4. Pepys M.B., Hirschfield G.M. C-reactive protein: a critical update. The Journal of Clinical Investigation 2003, 111:1805-1812.
5. Koenig W., Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. Arteriosclerosis, Thrombosis, and Vascular Biology 2007, 27:15-26.
6. Chen F., Eriksson P., Hansson G.K., Herzfeld I., Klein M., Hansson L.O., et al. Expression of matrix metalloproteinase 9 and its regulators in the unstable coronary atherosclerotic plaque. International Journal of Molecular Medicine 2005, 15:57-65.
7. Sluijter J.P.G., Pulskens W.P.C., Schoneveld A.H., Velema E., Strijder C.F., Moll F., et al. Matrix metalloproteinase 2 is associated with stable and matrix metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions: a study in human endarterectomy specimen pointing to a role for different extracellular matrix metalloproteinase inducer Glycosylation forms. Stroke 2006, 37:235-239.
8. Falk E., Shah P.K., Fuster V. Coronary plaque disruption. Circulation 1995, 92:657-671.
9. Graham M.M., Faris P.D., Ghali W.A., Galbraith P.D., Norris C.M., Badry J.T., et al. Validation of three myocardial jeopardy scores in a population-based cardiac catheterization cohort. American Heart Journal 2001, 142:254-261.
10. Sullivan D.R., Marwick T.H., Freedman S.B. A new method of scoring coronary angiograms to reflect extent of coronary atherosclerosis and improve correlation with major risk factors. American Heart Journal 1990, 119:1262-1267.
11. Zebrack J.S., Muhlestein J.B., Horne B.D., Anderson J.L. C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina. Journal of the American College of Cardiology 2002, 39:632-637.
12. Nissen S.E. Pathobiology, not angiography, should guide managementin acute coronary syndrome/non-ST-segment elevation myocardial infarction: the non-interventionist's perspective. Journal of the American College of Cardiology 2003, 41:S103-S112.
13. Drakopoulou M., Toutouzas K., Stefanadi E., Tsiamis E., Tousoulis D., Stefanadis C. Association of inflammatory markers with angiographic severity and extent of coronary artery disease. Atherosclerosis 2009, 206:335-339.
14. Arroyo-Espliguero R., Avanzas P., Quiles J., Kaski J.C. Predictive value of coronary artery stenoses and C-reactive protein levels in patients with stable coronary artery disease. Atherosclerosis 2009, 204:239-243.
15. Zacho J., Tybjaerg-Hansen A., Jensen J.S., Grande P., Sillesen H., Nordestgaard B.G. Genetically elevated C-reactive protein and ischemic vascular disease. The New England Journal of Medicine 2008, 359:1897-1908.
16. Nordestgaard B.G. Does elevated C-reactive protein cause human atherothrombosis? Novel insights from genetics, intervention trials, and elsewhere. Current Opinion in Lipidology 2009, 20:393-401.
17. Tayebjee M.H., Lip G.Y.H., Tan K.T., Patel J.V., Hughes E.A., MacFadyen R.J. Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease. The American Journal of Cardiology 2005, 96:339-345.
18. Rouy D., Ernens I., Jeanty C., Wagner D.R. Plasma storage at -80 degrees C does not protect matrix metalloproteinase-9 from degradation. Analytical Biochemistry 2005, 338:294-298.
19. Kai H., Ikeda H., Yasukawa H., Kai M., Seki Y., Kuwahara F., et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. Journal of the American College of Cardiology 1998, 32:368-372.
20. Castillo J., álvarez-Sabín J., Martínez-Vila E., Montaner J., Sobrino T., Vivancos J., et al. Inflammation markers and prediction of post-stroke vascular disease recurrence: the MITICO study. Journal of Neurology 2009, 256:217-224.
21. Welsh P., Whincup P.H., Papacosta O., Wannamethee S.G., Lennon L., Thomson A., et al. Serum matrix metalloproteinase-9 and coronary heart disease: a prospective study in middle-aged men. QJM 2008, 101:785-791.
22. Fukuda D., Shimada K., Tanaka A., Kusuyama T., Yamashita H., Ehara S., et al. Comparison of levels of serum matrix Metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris. The American Journal of Cardiology 2006, 97:175-180.
23. Nickelsen T.N. Data validity and coverage in the Danish national health registry. A literature review. Ugeskr Laeger 2001, 164:33-37.